Your account is not claimed yet. You can sign up with ORCID to claim your account.

Vidya Perera

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 12

Top Venues

Scientific reports

British journal of clinical pharmacology

Clinical pharmacokinetics

Clinical pharmacology and therapeutics

University of Sydney (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Sydney Mar 1o 2008 - Dec 1o 2011

Australia

PHD :: Pharmacy

Publications

Manting Chiang, Caroline Sychterz, Vidya Perera, Samira Merali, Maria Palmisano, Ian E Templeton, Lu Gaohua
Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype. Clinical pharmacology and therapeutics (2023)
Vidya Perera, Grigor Abelian, Danshi Li, Zhaoqing Wang, Liping Zhang, Susan Lubin, Wei Chen, Akintunde Bello, Bindu Murthy
Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants. Clinical pharmacokinetics 61 (6) (2022)
Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Scientific reports 12 (1) (2022)
Vidya Perera, Grigor Abelian, Danshi Li, Zhaoqing Wang, Liping Zhang, Susan Lubin, Akintunde Bello, Bindu Murthy
Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment. Clinical pharmacokinetics 61 (10) (2022)
Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Scientific reports 12 (1) (2022)
Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Scientific reports 12 (1) (2022)
Vidya Perera, Zhaoqing Wang, Susan Lubin, Takayo Ueno, Tomomi Shiozaki, Wei Chen, Xiaohui Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy
Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants. Scientific reports 12 (1) (2022)
Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Scientific reports 12 (1) (2022)
Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Scientific reports 12 (1) (2022)
Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy
Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor. Cardiology and therapy 11 (3) (2022)
Thomas M Polasek, Geoffrey T Tucker, Michael J Sorich, Michael D Wiese, Titus Mohan, Amin Rostami-Hodjegan, Porntipa Korprasertthaworn, Vidya Perera, Andrew Rowland
Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. British journal of clinical pharmacology 84 (3) (2018)
Vidya Perera, Joseph M Luettgen, Zhaoqing Wang, Charles E Frost, Cynthia Yones, Cesare Russo, John Lee, Yue Zhao, Frank P LaCreta, Xuewen Ma, Robert M Knabb, Dietmar Seiffert, Mary DeSouza, Pierre Mugnier, Brenda Cirincione, Takayo Ueno, Robert J A Frost
First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects. British journal of clinical pharmacology 84 (5) (2018)

Vidya Perera.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Vidya Perera